Benefit-Risk Considerations During Drug Product Development (8of14) REdI 2018

CDER’s Charu Mullick explains key considerations related to benefit and risk of investigational products during the development process. Mullick discusses the benefit-risk assessment framework in the context of hypothetical examples including monoclonal antibody products.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cdersbia
CDER SBIA 2018 Playlist: • 2018 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cderbsbialearn
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.gov/subscriptionm...
Email: [e-mail]
Phone: [phone] I [phone]